<code id='71291D279D'></code><style id='71291D279D'></style>
    • <acronym id='71291D279D'></acronym>
      <center id='71291D279D'><center id='71291D279D'><tfoot id='71291D279D'></tfoot></center><abbr id='71291D279D'><dir id='71291D279D'><tfoot id='71291D279D'></tfoot><noframes id='71291D279D'>

    • <optgroup id='71291D279D'><strike id='71291D279D'><sup id='71291D279D'></sup></strike><code id='71291D279D'></code></optgroup>
        1. <b id='71291D279D'><label id='71291D279D'><select id='71291D279D'><dt id='71291D279D'><span id='71291D279D'></span></dt></select></label></b><u id='71291D279D'></u>
          <i id='71291D279D'><strike id='71291D279D'><tt id='71291D279D'><pre id='71291D279D'></pre></tt></strike></i>

          knowledge

          knowledge

          author:entertainment    Page View:29
          Novo Nordisk headquarters -- health coverage from STAT
          LISELOTTE SABROE/Scanpix/AFP via Getty Images

          LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines. 

          Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure. 

          advertisement

          The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more
          States should stop sabotaging methadone treatment reform
          States should stop sabotaging methadone treatment reform

          Somearguethattakingmethadoneathomeisfarbetterthantrudgingtoacliniceveryday.KevinD.Liles/APSincetheFo

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Eliminate the waiting period for sterilization covered by Medicaid

          AdobeIt’stimetoacknowledgewhenalawintendedtorightanegregiouswronghasbecomeharmful—andchangeit.That’s